

H36.D2.B7 ANTI-TISSUE FACTOR LIGHT CHAIN VARIABLE REGION

GACATTCAGATGACCCAGTCTCCTGCCTCCAGTCTGCAATCTCTGGGAGAAAGTGTCACCATCACATGC  
D I Q M T Q S P A S Q S A S L G E S V T I T C

CTGGCAAGTCAGACCATTGATACATGGTTAGCATGGTATCAGCAGAAACCAGGGAAATCTCCTCAGCTC  
L A S Q T I D T W L A W Y Q Q K P G K S P Q L

CTGATTTATGCTGCCACCACTTGGCAGATGGGGTCCCATCAAGGTTCAAGTGGCAGTGGATCTGGCACA  
L I Y A A T N L A D G V P S R F S G S G S G T

AAATTTTCTTCAAGATCAGCAGCCCTACAGGCTGAAGATTTTGTAATATT TACTGTCAACAAGTTTAC  
K F S F K I S S L Q A E D F V N Y Y C Q Q V Y

AGTTCCTCATTACGTTTCGGTCTGGGACCAAGCTGGAGCTGAAA  
S S P F T F G A G T K L E L K

FIG. 1A

H36.D2.B7 ANTI-TISSUE FACTOR HEAVY CHAIN VARIABLE REGION

GAGATCCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCCTGGGCTTCAGTGCAGGTATCCTGCAAG  
E I Q L Q Q S G P E L V K P G A S V Q V S C K

ACTTCTGGTTACTCATTCACTGACTACAACGTGTACTGGGTGAGGCAGAGCCATGGAAGAGCCCTTGAG  
T S G Y S F T D Y N V Y W V R Q S H G K S L E

TGGATTGGATATATGATCCTTACAAATGGTATTACTATCTACGACCAGAACTTCAAGGGCAAGGCCACA  
W I G Y I D P Y N G I T I Y D Q N F K G K A T

TTGACTGTTGACAAGTCTTCCACCACAGCCCTTCATGCATCTCAACAGCCCTGACATCTGACGACTCTGCA  
L T V D K S S T T A F M H L N S L T S D D S A

GTTTATTCTGTGCAAGAGAIGTACTACGGCCCTTGACTTCTGGGGCCAAAGGCACCACTCTCACAGTC  
V Y F C A R D V T T A L D F W G Q G T T L T V

TCCTCA  
S S

FIG. 1B

ANTIBODY	APPARENT $K_1$ , M <sup>-1</sup>	APPARENT $K_1$ , M
BY ELISA		
D2	$5.2 \times 10^9$	$1.9 \times 10^{-10}$
I47	$6.5 \times 10^9$	$1.5 \times 10^{-10}$
K73	$9.8 \times 10^9$	$1.0 \times 10^{-10}$
K80	$2.3 \times 10^9$	$4.3 \times 10^{-10}$
L102	$2.5 \times 10^9$	$4.0 \times 10^{-10}$
L133	$1.7 \times 10^9$	$5.9 \times 10^{-10}$
BY BIACore		
H36	$3.1 \times 10^{10}$	$3.2 \times 10^{-11}$
I43	$2.3 \times 10^9$	$4.3 \times 10^{-10}$
I47	$3.2 \times 10^9$	$3.1 \times 10^{-10}$
L133	$4.6 \times 10^9$	$2.2 \times 10^{-10}$
M107	$1.1 \times 10^9$	$9.1 \times 10^{-10}$

FIG. 2

ANTIBODY NAME	% INHIBITION ANTIBODY PREINCUBATED WITH TF/VIIa
D1	0
D1B	1
H31	4
H36	95
I43	1
J131	7
K80	0
K82	0
K87	1
L97B	7
L101	0
L102	0
L105	0
L133	0
M5	1
M107	34

FIG. 3

ANTIBODY NAME	% INHIBITION TF PREINCUBATED WITH ANTIBODY PRIOR TO ADDITION OF VIIa	% INHIBITION TF PREINCUBATED WITH VIIa PRIOR TO ADDITION OF ANTIBODY
D1	15	nd
D1B	48	12.7
H31	64	21
H36	0	0
I43	68	55
J131	38	11
K80	12	nd
K82	0	nd
K87	0	nd
L96	0	nd
L101	38	11
L102	14	nd
L105	4	nd
L133	13	nd
M5	0	nd
M107	0	nd

FIG. 4

[rhTF], nM	[H36.D2], nM	H36.D2/rhTF MOLAR RATIO	CLOTTING TIME (SECONDS)	% INHIBITION OF rhTF FUNCTION
0.0048	0	0	102.3	0
	1.61	335.4	114.3	31.3
	3.23	670.8	121.3	45.8
0.023	0	0	77.6	0
	1.61	70.0	85.3	52.2
	3.23	140.0	91.1	65.2
	6.45	280.4	99.6	73.9
0.092	0	0	49.3	0
	3.23	35.1	65.8	65.2
	6.45	70.1	88.5	90.2
	12.90	140.2	113.3	95.7
0.46	0	0	32.6	0
	6.45	14.0	52.7	82.4
	12.90	28.0	80.2	96.7
	32.30	70.2	117.9	99.3
2.30	0	0	23.9	0
	16.10	7.0	47.1	94.4
	32.30	14.0	95.2	99.7
	64.50	28.0	115.3	99.9
11.52	0	0	22.2	0
	16.10	1.4	30.2	93.4
	32.30	2.8	46.0	98.8
	64.50	5.6	87.6	99.9
	161.30	14.0	114.0	100.0

FIG. 5




FIG. 6A




FIG. 6B

H36.D2 CONCENTRATION (ng)	<u>% INHIBITION</u> CELLS (TF/FVII) AND H36.D2 PREINCUBATED PRIOR TO FX ADDITION	<u>% INHIBITION</u> FX AND H36.D2 ARE ADDED SIMULTANEOUSLY TO CELLS (TF/FVII)
0	0	0
50	88	nd
100	92	nd
200	97	nd
800	nd	76
1600	nd	78
3200	nd	92

FIG. 7






FIG. 8A




FIG. 8B




Fig. 9A




Fig. 9B






Fig. 9C



**Fig. 10A**



**Fig. 10B**

## Lung Tumor




Fig. 11A




Fig. 11B




Fig. 11C

## Normal Lung



Fig. 11D




Fig. 11E




Fig. 12A




Fig. 12B




Fig. 12c




Fig. 12D